Mesenchymal Chondrosarcoma of the Infratemporal Fossa—A Rare Case Report

Shalender Sharma1*, J. K. Dayashankara Rao1, Harsh Jain2, Kaberi Majumder3, Neelima Gehlot1

1Department of Oral and Maxillofacial Surgery, SGT Dental College, Gurgaon, India
2Department of Oral and Maxillofacial Surgery, Sharada Dental College, Greater Noida, India
3Department of Orthodontics, SGT Dental College, Gurgaon, India
Email: Sharma.shalender@rediffmail.com

Received 5 January 2014; revised 4 February 2014; accepted 3 March 2014

Abstract
Chondrosarcoma is a malignant neoplasm that results in abnormal bone and cartilage growth. Although Chondrosarcoma is rare, it is the second most common primary bone malignancy. Mesenchymal Chondrosarcoma (MCS) is a rare histological variant of Chondrosarcoma (CS) that accounts for only 1% of all CS and has high predilection for the head and neck region with a peak incidence in 2nd and 3rd decade of life. There is comparable male to female ratio with two thirds of the cases arising from bone and one third from soft tissue. The tumor is unique because of its aggressive growth with a high tendency for late recurrence and delayed metastasis. We present a case of this highly malignant lesion arising from the infratemporal fossa and rapidly involving maxillary tuberosity and mandibular ramus.

Keywords
Chondrosarcoma; Mesenchymal Chondrosarcoma; Bone Neoplasm

1. Introduction
Mesenchymal Chondrosarcoma (MCS) is a rare tumour characterized by undifferentiated mesenchymal cells with islands of mature hyaline cartilage. Lichtenstein and Bernstein first described bony MCS in 1959. Dowling subsequently reported this entity in the soft tissue in 1964 [1].

MCS occurs most often in the second and third decades of life. It can occur anywhere in the body, both in skeletal and extra skeletal sites, including the orbit, viscera, meninges, or brain. However, it tends to occur 2 to 3
times more commonly in bones than in extra skeletal sites. In a review of 111 cases, 72 tumours occurred in skeletal sites, 22 of which affected the craniofacial bones; 38 tumours occurred in extra skeletal sites, with only 1 patient having orbital soft tissue involvement; and 1 occurred in both skeletal and extra skeletal sites [2]. It has a variable clinical course with frequent recurrence and occasional distant osseous and visceral metastatic spread. The prognosis is poor, independent of the type of treatment [3]. We are presenting a case report of MCS of infratemporal fossa in a young female which has involved maxillary tuberosity, ramus of the mandible and extending towards the temporal bone.

2. Case Report

A 23-year-old female reported in the OPD of oral surgery department with the complaint of swelling on the left side of the face since past 3 months. History revealed that the swelling is increasing progressively in size over the period of 3 months. Patient had restricted mouth opening and pain in the left maxillary tuberosity area since last 15 days. On examination a diffuse swelling was seen causing facial asymmetry on the left side of the face ovoid in shape measuring 8 × 6 cm in size. The swelling was firm in consistency, fixed to the underlying bone and non tender on palpation (Figure 1). No secondary changes of ulcer or sinus were seen and there was no sign of pus discharge. Intraorally no ulcerative growth was present. Expansion of the palatal as well as buccal cortical plate was present in the areas w.r.t 27 and 28 region. A provisional diagnosis of malignant bony neoplasm was given (Figure 1). Panoramic radiography revealed decreased radiodensity in the left maxillary tuberosity and ramus area. There was a typical sunburst appearance in the infratemporal area involving maxillary tuberosity, infratemporal bone and mandibular ramus area (Figure 2). CT scan revealed osteosclerosis and erosion of the
whole infratemporal fossa involving maxillary tuberosity, infratemporal surface of temporal bone and mandibular ramus area. A nonenhancing mass with mottled calcification was seen in the axial section measuring $5 \times 5$ cm in size. The classic sunburst appearance is also seen (Figures 3 and 4). An incisional biopsy was then done. Histologic examination revealed a biomorphic tumor displaying areas of well differentiated cellular hyaline cartilage surrounded by small undifferentiated tumor cells that exhibit a hemangiopericytoma like pattern of arrangement (Figure 5). The cartilaginous areas show prominent calcification with focal evidence of ossification. Tumor infiltration into bone is noted. Immunohistochemistry was done and the chondrocytes were positive for S100. Histopathology was suggestive of MS. The patient underwent surgery and chemotherapy.

Figure 3. CT axial view showing big mass in the infratemporal region.

Figure 4. 3D CT image of the lesion in infratemporal region.
3. Discussion

Phemister in 1930 defined Chondrosarcoma as sarcomas of bone containing abundant cartilage. Lichtenstein and Jaffe established criteria for classification of Chondrosarcoma. They defined Chondrosarcoma as arising from fully fledged cartilage and never containing osteoid or bone stroma [4]. According to international classification of diseases for oncology [5], CS has been classified into six subtypes, on the basis of the tumor location, the histological characteristics of the malignant cartilage cells and the makeup of the surrounding matrix material associated with the tumor are as follows: 1) Chondrosarcoma NOS (Not otherwise specified), 2) Juxtacortical Chondrosarcoma, 3) Myxoid Chondrosarcoma, 4) Mesenchymal Chondrosarcoma, 5) Clear cell Chondrosarcoma, 6) Dedifferentiated Chondrosarcoma.

MCS is a rare entity originally described by Lichtenstein and Bernstein as a biphasic tumour consisting of spindle cell mesenchyme mixed with areas of chondroid differentiation accounting for only about 1% of all Chondrosarcoma [4]. It develops from a pluripotent mesenchymal stem cell which can differentiate into angioblastic, fibroblastic and cartilaginous structures.

Approximately one-third of MCS are found outside bone within a variety of soft tissues, while two-thirds of these tumors are intraosseous. Most chondrosarcomas of the head and neck region occur in the maxilla; others are seen to occur less commonly in the body of the mandible, the ramus, the nasal septum and the paranasal sinuses [6]. In the maxilla, the most common location is anterior alveolus where preexisting nasal cartilage is present. Our case is one of the rare cases because it is occurring in the infratemporal fossa and involves maxillary tuberosity, infratemporal surface of maxilla and ramus of the mandible and extending towards the temporal bone.

MCS is more common during the second and third decades of life, therefore it is a malignancy of the young individuals as seen in our cases. There are no specific clinical signs or symptoms but the first clinical symptom is a painless swelling or mass, rapidly growing to a large size and leading to facial deformity, nasal obstruction, expansion of the bone and its subsequent perforation as it enlarges, surface ulceration may also be seen [7]. Later symptoms include pain and mobility of the teeth in the region. Rarely facial paralyses can also occur.

Radiographically, chondrosarcoma is seen as an irregularly shaped, ill-defined radiolucency with randomly scattered, opaque mottled areas. The lesion may appear lobulated and may elevate the adjacent periosteum to produce radiating laminae in a sunray pattern as seen in our case. Perforation of the cortex of the involved bone by a cartilaginous lesion is considered a sign of probable malignancy. Since these are not pathognomonic signs of chondrosarcoma the radiographic differential diagnosis also includes fibrosarcoma and osteosarcoma. Evaluation of the maxillary region on conventional radiographs is somewhat limited due to anatomical superimposition and two dimensional displays. CT performed with contrast enhancement is the imaging modality of choice because it best delineates the bony involvement while defining local invasion into the adjacent soft tissues as seen in both our reported cases [8].

Molecular pathology of mesenchymal chondrosarcoma has been evaluated with respect to differentiating it from other small cell sarcomas. Muller and co-workers [9] have found that it expresses type II collagen which differentiates it from other small cell sarcomas such as Ewing’s, synovial sarcoma and haemangiopericytoma.

Our case was characteristic of MC as dense population of anaplastic cells in a chondroid matrix was seen and
since there was marked cellular and nuclear pleomorphism, nuclear hyperchromasia; our case was considered high grade. Immunohistochemistry also can be done for difficult cases, chondroid areas are positive for S100 protein and neuron-specific enolase is focally positive for primitive mesenchymal cells. Our case was S100 positive for chondrocytes.

Wide surgical excision is the mainstay of treatment for MC in the jaw bones [10]. These tumors are radiore-sistant and chemotherapy can be used as an adjuvant therapy after wide surgical excision is made. The benefit of neo-adjuvant modalities for MC has not been proven. However the use of preoperative radiotherapy prior to radical resection has been shown to reduce tumour bulk [11]. Postoperative radiotherapy has been reported to increase survival rates although the studies done did not have statistically significant numbers of patients [12]. The overall survival rate at 5 and 10 years is 55% and 27% respectively [2]. Our case was treated with wide surgical excision followed by chemotherapy. Generally the prognosis of MC is considered to be poor and the grade, the size of the tumor, the adequacy of tumor resection margins may be prognostic indictors. Local recurrence occurs and may indicate subsequent metastasis; hence adequate treatment and long-term follow-up, including periodic systemic evaluation, are required for patients with MC of the maxillofacial region.

4. Conclusion

We present a case of MC, because MC is an uncommon tumor and is rarely found in the jaw. An adequate biopsy is enough for diagnosis. It may be radiolucent, radio-opaque or mixed. MCS requires surgical excision with wide margins. Pre- and postoperative chemotherapy or radiation may be a choice of treatment, although their effectiveness is unclear.

References